Periomics Care LLC
New York, NY
- UEI
- FLLTVXQCQ426
- CAGE
- 80NS0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 201 E 28th St #11-a, New York, NY 10016, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Zinc nanocrystals from zinc tetraammine fluoride for caries arrest and remineralization - abstract the who estimated… | National Institute of Dental and Craniofacial Research | $297,711 | |
| Modulation of the GUT microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma | National Cancer Institute | $399,752 | |
| A novel remedy for periodontal bone loss - periodontitis is a common chronic inflammatory disease characterized by… | National Institute of Dental and Craniofacial Research | $3,216,694 | |
| A novel remedy for periodontal bone loss | National Institute of Dental and Craniofacial Research | $221,537 |
About Periomics Care LLC
Periomics Care LLC is a biotechnology company based in New York focused on developing novel oral formulations for treating periodontal disease. It was established with the goal of commercializing a patented oral gel formulation called POC7A, which targets the succinate receptor SUCNR1 to reduce inflammation, alter the subgingival microbiome, and prevent bone loss associated with periodontal disease.
Through federal grant awards from the National Institutes of Health (NIH), Periomics Care LLC has received significant funding to advance the development of POC7A. In 2019, the company was awarded a $3.2 million Phase II STTR grant from the National Institute of Dental and Craniofacial Research (NIDCR) to scale up the synthesis and formulation of POC7A, conduct pharmacokinetic and toxicity studies in beagle dogs, and validate the efficacy of POC7A in a ligature-induced non-human primate model of periodontal disease. Additionally, the company received a $399,752 grant from the National Cancer Institute (NCI) in 2020 to investigate the modulation of the gut microbiome to enhance the efficacy of immunotherapy in pancreatic adenocarcinoma. Periomics Care LLC has also been awarded a $221,537 Phase I grant from NIDCR for the initial development of POC7A as a novel remedy for periodontal bone loss.
Quick answers
What is Periomics Care LLC's UEI?
Periomics Care LLC's Unique Entity ID (UEI) in SAM.gov is FLLTVXQCQ426.
What is Periomics Care LLC's CAGE code?
Periomics Care LLC's CAGE code is 80NS0.
What is Periomics Care LLC's primary NAICS code?
Periomics Care LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Periomics Care LLC located?
Periomics Care LLC's physical address in SAM.gov is 201 E 28th St #11-a, New York, NY 10016, USA.
Is Periomics Care LLC registered in SAM.gov?
Yes. Periomics Care LLC's SAM.gov registration is active through December 1, 2026.
What is Periomics Care LLC's most recent federal award?
Periomics Care LLC's most recent federal grant award is Zinc nanocrystals from zinc tetraammine fluoride for caries arrest and remineralization - abstract the who estimated… (R41DE034627), from National Institute of Dental and Craniofacial Research, on August 6, 2025.
On GovTribe
See Periomics Care LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors